Home > Research > Publications & Outputs > Troleandomycin as an oral corticosteroid sparin...
View graph of relations

Troleandomycin as an oral corticosteroid sparing agent in stable asthma

Research output: Contribution to journalJournal articlepeer-review

Published
  • David J. Evans
  • Paul Cullinan
  • Duncan M. Geddes
  • E. Haydn Walters
  • Stephen Milan
  • Paul Jones
Close
<mark>Journal publication date</mark>23/10/2000
<mark>Journal</mark>Cochrane Database of Systematic Reviews
Publication StatusPublished
<mark>Original language</mark>English

Abstract

Abstract
Background

Patients with chronic severe asthma are often dependent on the long term prescription of oral corticosteroids. The use of steroids is associated with serious side effects. Physicians treating such patients continue to search for alternative therapies that reduce the need for chronic dosing with oral steroids. Troleandomycin is a compound that is established as an effective antibiotic but may also have non-antibacterial actions that may be useful in the treatment of asthma.

Objectives

The objective of this review was to assess the effects of adding troleandomycin to oral steroids in the treatment of chronic steroid dependent asthmatics.

Search methods

The Cochrane Airways Group Specialised Register and reference lists of identified articles were searched. Searches are current as of September 2010.

Selection criteria

Randomised trials looking at the addition of troleandomycin compared to placebo in adult steroid dependent asthmatics.

Data collection and analysis

Trial quality was assessed and data extraction was carried out by two reviewers independently. Study authors were contacted for missing information.

Main results

Three trials fulfilled the criteria for inclusion in the review and a total of 112 patients were recruited into these studies. Data from 90 patients were analysed. There was no treatment effect for troleandomycin in terms of steroid dose reduction (SMD -0.29, 95% CI -0.75, 0.17). For measures of lung function a meta-analysis of data derived from two of the included studies showed no benefits for added troleandomycin (SMD 0.06 95% CI -0.8, 0.9).

Authors' conclusions

There is insufficient evidence to support the use of troleandomycin in the treatment of steroid dependent asthma.



Plain language summary
Troleandomycin as an oral corticosteroid sparing agent in stable asthma

Troleandomycin is a macrolide antibiotic with established effects in the treatment of infections. It alters the breakdown of corticosteroid drugs, so may be of benefit in asthma. This review found three small studies, that provide no evidence to justify the use of this drug in asthma.